临床肝胆病杂志2018，Vol.34Issue(2)：424-428,5.DOI:10.3969/j.issn.1001-5256.2018.02.046
靶向药物治疗肝细胞癌的最新进展
Recent advances in targeted drug therapy for hepatocellular carcinoma
樊永强 1董胜利1
作者信息
- 1. 山西医科大学第二临床医学院普外科,太原030001
- 折叠
摘要
Abstract
More and more clinical trials have proved the efficacy of targeted drugs in the treatment of hepatocellular carcinoma (HCC).With the development of science and technology,more and more targeted drugs have appeared.In recent years,targeted drugs such as regorafenib and ramucirumab have shown great potential in related clinical trials.In addition,there are ongoing clinical trials for second-linecandidate drugs,such as c-Met inhibitors tivantinib and cabozantinib and a VEGFR-2 inhibitor ramucirumab.This article summarizes the advances in targeted drug therapy for HCC and related trial data,which provides a reference for further clinical trials and treatment.关键词
癌,肝细胞/靶向药物/药物疗法/临床试验/综述Key words
carcinoma, hepatocellular/targeted drug/drug therapy/clinical trial/review分类
医药卫生引用本文复制引用
樊永强,董胜利..靶向药物治疗肝细胞癌的最新进展[J].临床肝胆病杂志,2018,34(2):424-428,5.
